Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (note: input metadata referenced "Viridian Therapeutics," but the filing text identifies Miragen) on January 24, 2019, reporting an event that occurred on January 21, 2019. The registrant is a Delaware corporation and an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual amendment rather than financial performance data.
Material Changes
On January 21, 2019, the Company entered into an eighth amendment to its License and Collaboration Agreement with Les Laboratoires Servier and Institut de Recherches Servier (the "Servier Agreement"). The amendment, effective January 7, 2019, updates Section 3.8 of the agreement regarding committee record keeping.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. The Company anticipates filing the full text of the Amendment with its annual report on Form 10-K for the fiscal year ended December 31, 2018.
Investor Verification Checklist
- Verify the full text of the eighth amendment to the Servier Agreement in the upcoming Form 10-K.
- Confirm the specific operational impact of the updated committee record-keeping provisions in Section 3.8.
- Review the Company's status as an emerging growth company for potential differences in financial reporting standards.